At 5.5 years, initial SNM therapy was less costly ($23,504 vs. $27,720) and more effective than initial BTX (4.08 vs. 4.04 QALYs). Probabilistic sensitivity analyses that varied SNM and BTX success and repeat BTX injection probabilities and utilities, confirmed these results. Repeat injections and differences in AEs were responsible for most of the changing costs over time. CONCLUSIONS: Based on a more clinically comprehensive design and set of inputs than previous models, treatment with SNM may be more cost-effective than BTX, especially over longer periods of time.
OBJECTIVES: Cytomegalovirus (CMV) disease can severely impact patient outcomes and costs associated with kidney transplant. The IMPACT study has shown that kidney transplant patients significantly benefit from extending valganciclovir prophylaxis from 100 to 200 days. The objective of this study was to determine the cost-effectiveness of valganciclovir 200 day prophylaxis compared to 100 days in kidney transplant patients at high-risk for developing CMV disease. METHODS: A Markov model was developed to capture time spent by patients in various health states, which included: CMV, No-CMV, Acute Rejection, Graft Failure, Dialysis and Death. Results were reported as incremental cost per additional quality adjusted life-years (QALY) gained, over a 10-year period. Transition probabilities for the first year were derived from the IMPACT study. Data beyond the first year were derived from the published literature and baseline mortality rate was determined from the Canadian Organ Replacement Register. The base case analysis focused on direct medical costs only from the perspective of the Ministry of Health (MoH). A second analysis was conducted from the societal perspective. Cost data were obtained from a variety of sources and reported as 2010 Canadian Dollars. A 5% discount rate was applied to both costs and patient outcomes. Multiple sensitivity analyses were undertaken to test the robustness of the model. RESULTS: From the MoH perspective valganciclovir 200 days prophylaxis is cost-effective when compared to 100 days with an incremental cost-utility ratio (ICUR) of $34,818 per additional QALY gained. The cost-effectiveness is improved from the societal perspective, with an ICUR of $32,571 per additional QALY gained. Results were robust over a wide range of sensitivity analyses tested. CONCLUSIONS: Valganciclovir 200 days is a costeffective prophylaxis strategy in kidney transplant patients at high-risk of developing CMV when compared to valganciclovir 100 days.
PUK17 UTILIZATION AND ECONOMIC IMPACT OF IV IRON AND ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS: A MULTI-HOSPITAL STUDY
Joshi AD, Holdford D, Brophy D, Harpe SE Virginia Commonwealth University, Richmond, VA, USA OBJECTIVES: The rate and extent of utilization of IV iron in anemic CKD patients was quantified. Predictors of IV iron and ESA use were determined. The impact of IV iron and ESA use was examined separately for total hospital costs and length of stay (LOS). METHODS: This is a retrospective cohort analysis within the UHC data warehouse in the period of January 1, 2006 , to December 31, 2008 . Inclusion criteria were age Ͼ 18 years with a primary/secondary diagnosis of CKD. The exposure of interest was IV iron and ESA therapy, and the outcome was the difference in total hospital costs and length of stay. A binomial logistic regression using the GEE methodology was used to identify predictors of IV iron utilization. Propensity scores were used to control for confounding. A GEE model using gamma distribution and log link was used to determine the adjusted hospital cost and length of stay for the IV iron and ESA and ESA alone therapy groups. RESULTS: 82,947 patients met the study criteria. Of the 82,947 CKD patients on ESA therapy, only 8% (n ϭ 6678) patients were on IV iron supplementation. Age, race, primary payer, admission status, severity of illness, dialysis status and physician specialty were identified as strong predictors of IV iron use. For patients using both IV iron and ESA (nϭ6678), mean costs were $34,756 compared to $31,404 for ESA users alone (nϭ76,269). The overall mean LOS for all patients was 9.75 days. For those using IV iron, the LOS was 10.71 days, and for those only using ESA, the LOS was 9.66 days. CONCLUSIONS: Our investigation showed significant reduction in ESA doses with the use of IV iron supplementation, however, the overall prevalence of IV iron usage was low. Intravenous iron users were associated with a higher total hospital cost and longer length of stay than ESA users.
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PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL): DEVELOPMENT OF A CONCEPTUAL FRAMEWORK
Cole JC 1 , Krasa HB 2 , Cheng R 1 , Oberdhan D 2 , Urwongse J 3 , Schaefer C 3 , Czerwiec F 2 1 Covance Market Access Services, Inc., San Diego, CA, USA, 2 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, 3 Covance Market Access Services, Inc., Gaithersburg, MD, USA OBJECTIVES: The aim of our study was to construct the conceptual framework of the impact of ADPKD on patients to support the use or development of a HRQoL instrument in ADPKD. METHODS: Based on concepts identified from the literature and ADPKD physicians/researchers from North America, Europe, and Japan, patients were asked how ADPKD impacts their physical and social functioning, emotions, and urinary symptoms according to a pre-defined moderator guide. Twenty focus groups (FGs) were conducted across 11 sites: three cities in North America (nϭ42), six cities in Europe (nϭ64), and two cities in Japan (nϭ11). FGs were moderated by native speakers and overseen onsite by a US-based scientist. A saturation table was developed to summarize concepts discussed in the FGs; saturation was achieved once no new concepts were identified. Concepts were identified based on themes mentioned by Ն2 participants within a FG. RESULTS: Concepts generated from the literature and ADPKD physicians/researchers discussions were endorsed by ADPKD patients. Agreement of concepts between genders across all countries was observed. Twenty-eight concepts were identified and categorized into: Physical Impact (impact on work/housework, limited functioning with mild/moderate exertion, self-care, diminish sex/intimacy, pain/discomfort in extremities/core, pain affecting work/housework, pain occurring with activity, modifications in lifestyle), Emotional Impact (fatigue, depression, anxiety, guilt of passing it to children, acceptance/self-education), Urinary Concerns (urgency, frequency, nocturia). Other concepts identified by patients include effect on diet, concern over body image, thirst, and disruption of social/leisure activities. Fifty-seven percent of these concepts were identified in the first FG; 100% saturation was achieved in the fifth FG. CONCLUSIONS: Identified concepts were universally applicable and their strength is evident by the achievement of complete saturation after 25% of the FGs. The completion of this conceptual framework using an iterative process provides a strong basis to develop an ADPKD-specific HRQoL instrument.
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PUK19 KIT73: PRELIMINARY REPORTS OF IMMUNOSUPRESSANT THERAPY PATTERNS IN A COHORT OF POST KIDNEY TRANSPLANT PATIENTS IN BRAZIL
OBJECTIVES: Many patients with OAB attempt self-management and are reluctant to initiate an OAB discussion with a physician. We sought to identify patient characteristics associated with patient initiation of an OAB discussion with a physician. METHODS: Of 24,866 respondents of the 2009 National Health & Wellness Survey, an internet-based questionnaire on healthcare attitudes, behaviors, and outcomes, 2750 recontacted respondents qualified for and completed a longitudinal survey. Eligible subjects (Ն18 y) had an OAB Awareness Total score of Ͼ14 (men) or Ͼ16 (women) or used an OAB prescription medication. Exclusion criteria included current pregnancy or catheter use, hematuria, urinary tract infection symptoms, benign prostatic hyperplasia (BPH), use of BPH medication, or prostate cancer. Analysis of proportions and logistic regression analysis (2-tailed PϽ0.05 significance level) identified patient characteristics associated with initiation of OAB discussions with a physician. RESULTS: 1325 of 2750 (48%) OAB patients reported initiating an OAB discussion with a physician. These respondents (mean age 52 y) were predominantly female (65%) and white (71%). Significant variables associated with initiation of an OAB discussion were divorced/separated/widowed vs single, more familiar with OAB, a longer duration of bladder control symptoms, lower SF-12 Physical Component Summary score, better daily activity function, greater pill burden, and regular physician contact (Table) . Patient age, income, employment status, and health insurance coverage were not significantly associated with a patient-physician OAB discussion. CONCLUSIONS: Patients are more likely to initiate an OAB discussion with their physician if they have regular contact with the physician, a longer duration of symptoms, are familiar with OAB, and have worse physical quality of life. Socioeconomic variables or drug insurance coverage were not significantly associated. These findings suggest that the physician relationship is important for help seeking behavior; and there is a need for early patient education on OAB symptoms and treatments. OBJECTIVES: Determine the impact of correcting for different definitions of prostate-specific antigen (PSA) recurrence when analyzing relative effectiveness of seven treatments for localized PC; Emphasize the importance of clinical input and real-world data in ensuring modeling accuracy. METHODS: We conducted two lifetime cost-utility analyses comparing men undergoing open, laparoscopic, or robot-assisted radical prostatectomy, 3-dimensional conformal or intensity-modulated radiation therapy, brachytherapy, or combined external-beam radiation and brachytherapy. We constructed a Markov model quantifying lifetime costs and quality-adjusted life years (QALYs) for men with localized PC in low-, intermediate-, and high-risk strata. Post-treatment PSA recurrence is defined differently for surgical versus radiation treatments. In Study 1, we made clinically-based corrections in time between recurrence and metastasis, the basis for time-to-diseaseprogression (biochemical failure [BCF]) calculations, to account for the different definitions. In Study 2, these corrections were not made. RESULTS: In "corrected" analyses, surgery tended to yield more QALYs and lower costs than radiation, with minimal differences among surgical modalities. Compared to a base case assuming a 4-year increment between the surgery and radiation modalities in the median time from BCF to metastasis, "uncorrected" analyses yield surgical costs relatively overstated by 3 to 11%; QALYs understated by 1 to11%; life expectancy understated by Ͻ1% to 8.5%; metastasis overstated by 17 to 36%; and PC death overstated by 17% to 43%. Results are generally greater with larger corrections and outcomes discounted to net present value. CONCLUSIONS: "Without correction" results do not affect conclusions about relative costs for all patients or QALYs for low-risk patients. They do affect QALY conclusions for intermediate-and higher-risk patients, yielding erroneous conclusions on the relative superiority of radiation versus surgical treatments. Without correction, the same incorrect conclusions would be reached for survival, metastasis, and PC death. Literature and real-world data were used to validate the corrections.
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PUK22 LEVELING THE PLAYING FIELD: A CASE STUDY ON TECHNICAL PRECISION IN COMPARATIVE EFFECTIVENESS RESEARCH FOR CLINICALLY LOCALIZED PROSTATE CANCER (PC)
PUK23
METHODOLOGICAL CONSIDERATIONS FOR COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY
Globe D 1 , Carlson J 2 , Patel H 3 , Colayco D 1 , Hansen RN 2 , Watanabe J 2 , Sullivan SD 2 1 Allergan LLC, Irvine, CA, USA, 2 University of Washington, Seattle, WA, USA, 3 Allergan, LLC, Marlow Buckinghamshire, UK OBJECTIVES: Selection of an appropriate modeling structure is a key consideration in economic evaluations. Factors that influence the choice of modeling structure include data availability and consensus within the clinical community regarding clinically meaningful definitions of treatment response and defined and measureable health states. In the absence of an agreed consensus, selecting a model structure is challenging. We explored two model structures to assess the cost-effectiveness of onabotulinumtoxinA for the treatment of urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO). METHODS: The merits and limitations of a model based on treatment response versus an absolute model structure were considered. In the response model, health states were defined by precise trial outcomes (percent reduction in UI episodes from baseline). In the absolute model, health states were defined by categories of UI episodes/week. In the absence of clinically meaningful cutoffs, we plotted health-related quality of life (HRQoL) scores versus UI episodes to derive meaningful cutoffs for health states based on HRQoL. RESULTS: In the response model, response was defined as a Ն50% reduction in UI episodes. The primary limitation with this approach is the heterogeneity within 'non-responder' patients (e.g. patients with either a 0% or a 49% reduction are both 'non-responders'). No clear health state cutoffs were observed with respect to HRQoL and UI episodes for the absolute model. Health states were defined on percentile distribution within the trial population: dry, 0-25% [1-14 UI episodes/ week], Ͼ25%-75% [15-32 UI episodes/week], and Ͼ75% [Ͼ32 UI episodes/week]. The primary limitations to this approach are the inability to capture health improvement within health states and the lack of clinical relevance for health states based on percentiles. CONCLUSIONS: In the absence of clinical consensus, model structure selection should be a key consideration to capture the true economic value of a therapy.
PUK24
USE OF BIOMARKERS IN PROPENSITY SCORE MATCHING TO MITIGATE CHANNELING BIAS IN A RETROSPECTIVE COHORT OF ESRD PATIENTS
Wilson SM, Rubin JL DaVita Clinical Research, Minneapolis, MN, USA OBJECTIVES: Retrospective analyses are inherently subject to bias. Techniques such as propensity score matching (PSM) can function as pseudo-randomization. The PSM, however, is often done solely using administrative claims data. We tested the hypothesis that claims alone would provide inadequate matching when compared to claims plus relevant biomarkers. METHODS: We used databases from a large dialysis organization to obtain two cohorts of dialysis patients prescribed different drug therapies within the same class. The cohorts were first matched on demographics and comorbidities only. The same cohorts were then rematched, adding baseline biomarkers (albumin, corrected calcium, Kt/V, normalized protein catabolic rate (nPCR), parathyroid hormone (PTH), phosphorus) to the PSM. We used generalized mixed models (GMM) to determine if treatment was associated with lab outcomes over a 16-week period, run separately on both PSM cohorts. RESULTS: The first PSM cohorts did not differ on baseline demographic and comorbid variables, but significant differences existed in four (nPCR, phosphorus, calcium, PTH) of the six baseline biomarkers excluded from the match (all pϽ 0.01). When biomarkers were included in the PSM, there were no significant differences between groups on any baseline measures. GMM analysis showed a significant A78
